UP!
 |
|
|
Type
|
Public |
|---|---|
| Traded as |
|
| Industry | Orthodontics devices |
| Founded | 1997 |
| Founders | Zia Chishti, Kelsey Wirth |
| Headquarters | San Jose, California, USA |
|
Area served
|
Worldwide |
|
Key people
|
Joseph M. Hogan (President) & (CEO) |
| Products | clear aligners, scanners |
| Revenue |  $ 1.080 billion(FY 2016) |
|
Operating income
|
$ 248.92 million (FY 2016) |
|
Net income
|
$ 189.68 million (FY 2016) |
| Total assets | $ 1.396 billion (FY 2016) |
| Total equity | $ 995.39 million (FY 2016) |
|
Number of employees
|
6,060 (Dec 2016) |
| Website | www.aligntech.com |
Align Technology is a manufacturer of 3D digital scanners and a clear aligners used in orthodontics. It is headquartered in San Jose, California; it manufactures the aligners in Juarez, Mexico and its scanners in Israel.
Align Technology was founded by Zia Chishti and Kelsey Wirth in 1997 and began working on the development of a clear aligner. Align received FDA clearance to market the Invisalign system in 1998 and it was first marketed in 2000. Align Technology went public on January 26, 2001 on the Nasdaq Stock Market.
In 2010 the company received a warning letter from the FDA regarding its failure to report serious reactions to Invisalign.
In March 2011 Align acquired the Israeli company Cadent for $190 million; Cadent manufactured intraoral cameras that included 3D scanners, as well as software to display the acquired images and to plan treatment.
Joseph M. Hogan joined Align in June 2015, and serves as CEO and President. As of 2016 it had 6,060 employees worldwide.
The company's sales reached $1 billion for the first time in 2016 and its products were being used in about 8% of people who got braces. In 2017 the company was faced with the challenge of the expiration of its patents on its Invisalign system starting in October 2017 and the beginning of generic competition.
| Period | Date | Adjusted Actuals EPS | GAAP EPS |
|---|---|---|---|
| Q4 2022 | 2023-02-01 | 1.73 | 1.73 |
| Q3 2022 | 2022-10-26 | 1.36 | 1.36 |
| Q2 2022 | 2022-07-27 | 2.00 | 2.00 |
| Q1 2022 | 2022-04-27 | 2.13 | 2.13 |
| Q4 2021 | 2022-02-02 | 2.83 | 2.83 |
| Q3 2021 | 2021-10-27 | 2.87 | 2.87 |
| Q2 2021 | 2021-07-28 | 3.04 | 3.04 |
| Q1 2021 | 2021-04-28 | 2.49 | 2.49 |
| Q4 2020 | 2021-02-03 | 2.61 | 2.61 |
| Q3 2020 | 2020-10-21 | 2.25 | 2.25 |
| 2016-06-04 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-06-04 | Reiterated Rating | Robert W. Baird | Buy | |
| 2016-06-04 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-06-04 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-05-17 | Reiterated Rating | Piper Jaffray | Overweight | $74.00 to $82.00 |
| 2016-05-17 | Reiterated Rating | Piper Jaffray Cos. | Overweight | $74.00 to $82.00 |
| 2016-05-14 | Reiterated Rating | Morgan Stanley | Buy | |
| 2016-05-11 | Initiated Coverage | Credit Suisse | Outperform | $84.00 |
| 2016-04-29 | Reiterated Rating | Morgan Stanley | Buy | $84.00 |
| 2016-04-29 | Reiterated Rating | Jefferies Group | Buy | $85.00 |
| 2016-03-24 | Reiterated Rating | Canaccord Genuity | Buy | $72.00 to $80.00 |
| 2016-03-23 | Boost Price Target | Roth Capital | Buy | $72.00 to $80.00 |
| 2016-03-08 | Reiterated Rating | Piper Jaffray | Buy | |
| 2016-01-29 | Reiterated Rating | Roth Capital | Buy | |
| 2016-01-29 | Reiterated Rating | William Blair | Buy | |
| 2016-01-29 | Boost Price Target | Robert W. Baird | Outperform | $72.00 to $74.00 |
| 2016-01-29 | Reiterated Rating | Leerink Swann | Outperform | $75.00 to $81.00 |
| 2016-01-29 | Boost Price Target | Jefferies Group | Buy | $72.00 to $75.00 |
| 2016-01-29 | Boost Price Target | Goldman Sachs | Buy | $67.00 to $72.00 |
| 2016-01-29 | Boost Price Target | Stifel Nicolaus | Buy | $80.00 to $82.00 |
| 2016-01-29 | Boost Price Target | Goldman Sachs Group Inc. | Buy | $67.00 to $72.00 |
| 2016-01-20 | Reiterated Rating | Roth Capital | Buy | |
| 2015-11-18 | Initiated Coverage | Piper Jaffray | Overweight | $74.00 |
| 2015-10-25 | Reiterated Rating | Leerink Swann | Buy | $70.00 to $75.00 |
| 2015-10-23 | Reiterated Rating | William Blair | Outperform | |
| 2015-10-23 | Boost Price Target | Robert W. Baird | Outperform | $68.00 to $72.00 |
| 2015-10-23 | Boost Price Target | Jefferies Group | Buy | $70.00 to $72.00 |
| 2015-10-23 | Boost Price Target | Stifel Nicolaus | Buy | $75.00 to $80.00 |
| 2015-10-20 | Reiterated Rating | Roth Capital | Buy | |
| 2015-09-11 | Initiated Coverage | Leerink Swann | Outperform | $70.00 |
| 2015-07-24 | Boost Price Target | Stifel Nicolaus | Buy | $70.00 to $75.00 |
| 2015-07-16 | Reiterated Rating | Roth Capital | Buy | |
| 2015-06-19 | Reiterated Rating | Roth Capital | Buy | $72.00 |
| 2015-04-24 | Reiterated Rating | Stifel Nicolaus | Buy | $65.00 to $70.00 |
| 2015-04-24 | Set Price Target | Roth Capital | Buy | $62.00 to $72.00 |
| 2015-04-21 | Upgrade | Morgan Stanley | Equal Weight to Overweight | $56.00 to $79.00 |
| 2015-02-03 | Lower Price Target | Roth Capital | Buy | $66.00 to $62.00 |
| 2015-01-30 | Lower Price Target | Jefferies Group | Buy | $72.00 to $70.00 |
| 2015-01-30 | Downgrade | JMP Securities | Outperform to Market Perform | $63.00 |
| 2015-01-26 | Set Price Target | Roth Capital | Buy | $66.00 to $62.00 |
| 2015-01-02 | Upgrade | Robert W. Baird | Neutral to Outperform | $53.00 to $64.00 |
| 2014-10-24 | Upgrade | Jefferies Group | Hold to Buy | $62.00 |
| 2014-10-20 | Upgrade | Credit Suisse | Neutral to Outperform | $58.00 |
| 2014-10-20 | Upgrade | Goldman Sachs | Neutral to Buy | |
| 2014-07-25 | Reiterated Rating | Jefferies Group | Hold | $55.00 to $60.00 |
| 2014-04-24 | Reiterated Rating | Credit Suisse | Neutral | $58.00 |
| 2014-04-24 | Reiterated Rating | Cantor Fitzgerald | Positive | |
| 2014-04-07 | Upgrade | Barrington Research | Market Perform to Outperform | $67.00 |
| 2014-04-04 | Reiterated Rating | Cantor Fitzgerald | Buy | |
| 2014-01-31 | Boost Price Target | Roth Capital | $56.00 to $66.00 | |
| 2014-01-31 | Boost Price Target | JMP Securities | $64.00 to $74.00 | |
| 2014-01-29 | Boost Price Target | Stifel Nicolaus | Buy | $60.00 to $65.00 |
| 2014-01-28 | Boost Price Target | Cantor Fitzgerald | $60.00 to $65.00 | |
| 2013-10-18 | Reiterated | Stifel | Buy | $54 to $57 |
| 2013-10-18 | Boost Price Target | Roth Capital | Buy | $46.00 to $56.00 |
| 2013-10-18 | Boost Price Target | Jefferies Group | Hold | $43.00 to $52.00 |
| 2013-10-18 | Reiterated Rating | Robert W. Baird | Hold | $49.00 |
| 2013-10-18 | Boost Price Target | Stifel Nicolaus | Buy | $54.00 to $57.00 |
| 2013-10-18 | Upgrade | Cantor Fitzgerald | Hold to Buy | $42.00 to $60.00 |
| 2013-10-04 | Downgrade | Robert W. Baird | Outperform to Neutral | $49.00 |
| 2013-09-17 | Reiterated | Stifel | Buy | $46 to $54 |
| 2013-09-17 | Boost Price Target | Stifel Nicolaus | Buy | $46.00 to $54.00 |
| 2013-07-19 | Reiterated | Stifel | Buy | $43 to $46 |
| 2013-07-19 | Reiterated | Cantor Fitzgerald | Hold | $40 to $42 |
| 2013-07-10 | Reiterated | Stifel | Buy | $40 to $43 |
| 2013-07-02 | Initiated | Robert W. Baird | Outperform | $45 |
| 2013-06-17 | Reiterated | Stifel | Buy | $38 to $40 |
| 2013-02-04 | Reiterated | Stifel Nicolaus | Buy | $32 to $38 |
| 2012-11-08 | Initiated | Stifel Nicolaus | Buy | $32 |
| 2012-10-18 | Reiterated | Cantor Fitzgerald | Hold | $37 to $32 |
| 2012-09-17 | Downgrade | Cantor Fitzgerald | Buy to Hold | $37 |
| 2012-05-22 | Initiated | Cantor Fitzgerald | Buy | $37 |
| 2012-04-25 | Reiterated | Barrington Research | Outperform | $28 to $38 |
| 2012-02-01 | Reiterated | Barrington Research | Outperform | $24 to $28 |
| 2012-01-31 | Reiterated | JMP Securities | Mkt Outperform | $26 to $29 |
| 2011-12-16 | Initiated | William Blair | Outperform | |
| 2010-09-15 | Initiated | JMP Securities | Mkt Outperform | $23 |
| 2016-06-04 | Reiterated Rating | Credit Suisse | Buy | |
| 2016-06-04 | Reiterated Rating | Robert W. Baird | Buy | |
| 2016-06-04 | Reiterated Rating | Leerink Swann | Buy | |
| 2016-06-04 | Reiterated Rating | Credit Suisse Group AG | Buy | |
| 2016-05-17 | Reiterated Rating | Piper Jaffray | Overweight | $74.00 to $82.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In ALGN 512 funds of 2213 total. Show all
| Fund name | Ticker shares |
|---|---|
| Vanguard Group, Inc | 8.21M |
| BlackRock Inc. | 5.59M |
| EDGEWOOD MANAGEMENT LLC | 3.88M |
| STATE STREET CORP | 3.02M |
| BlackRock Fund Advisors | 2.97M |
| WELLINGTON MANAGEMENT CO LLP | 2.50M |
| BlackRock Institutional Trust Company, N.A. | 2.35M |
| SANDS CAPITAL MANAGEMENT, LLC | 2.32M |
| POLEN CAPITAL MANAGEMENT LLC | 1.99M |
| PRICE T ROWE ASSOCIATES INC /MD/ | 1.85M |
| ALLIANCEBERNSTEIN L.P. | 1.61M |
| GEODE CAPITAL MANAGEMENT, LLC | 1.51M |
| HENDERSON GROUP PLC | 1.29M |
| Capital World Investors | 1.12M |
| MORGAN STANLEY | 0.93M |
| Name Relationship | Total Shares | Holding stocks |
|---|---|---|
| DANAHER CORP /DE/ | 4.75% (3837132) | ALGN / DHR / |
| LACOB JOSEPH | 0.37% (296264) | ALGN / OREX / |
| PRESCOTT THOMAS M President and CEO | 0.17% (140399) | ALGN / |
| LARKIN C RAYMOND JR | 0.10% (83201) | ALGN / HTWR / |
| HEDGE LEN SVP, Business Operations | 0.07% (55861) | ALGN / |
| MORROW GEORGE J | 0.06% (51400) | ALGN / NBIX / OTIC / SWY / VICL / |
| HOGAN JOSEPH M President and CEO | 0.06% (50211) | ALGN / |
| Thaler Warren S | 0.06% (47400) | ALGN / |
| Wright Emory VP, Operations | 0.05% (41823) | ALGN / |
| Pascaud Raphael VP, International | 0.04% (35587) | ALGN / |
| AROLA KENNETH VP, Finance and CFO | 0.04% (31682) | ALGN / EXTR / |
| NAGEL DAVID C | 0.04% (30200) | ALGN / TSRA / UPIP / VG / |
| Kolli Sreelakshmi VP, Info Technology | 0.03% (28180) | ALGN / |
| COLLINS DAVID E | 0.03% (25900) | ALGN / |
| Relic Zelko VP, Research & Development | 0.03% (24534) | ALGN / |
| Tay Julie VP, Asia Pacific | 0.02% (19866) | ALGN / |
| SANTORA GREG J | 0.02% (19000) | ALGN / SALE / |
| Saia Andrea Lynn | 0.02% (18133) | ALGN / CCE / |
| WHITE DAVID L CFO | 0.01% (11549) | ALGN / |
| Erfurth Jennifer VP, Global HR | 0.01% (10760) | ALGN / |
| Olson Jennifer VP& Mng Dir. D-DCC | 0.01% (9487) | ALGN / |
| Puco Christopher C. VP, No. American Sales | 0.01% (8623) | ALGN / |
| GEORGE ROGER E VP,Leg. Affairs & Gen. Counsel | 0.01% (8068) | ALGN / |
| Beard Simon VP and Mgng Director, EMEA | 0.01% (7472) | ALGN / |
| Hockridge Stuart A VP, Global Human Resources | 0.01% (4856) | ALGN / |
| Twomey Richard M.L. VP, International | 0.01% (4272) | ALGN / |
UM